Multiple Sclerosis Therapeutics Market Report

Multiple Sclerosis Therapeutics Market Analysis By Drug Class (Immunomodulators, Immunosuppressant, Copaxone, Avonex, Gilenya, Tysabri, Betaseron, Tecfidera, Rebif, Ampyra, Aubagio, Extavia, Plegridy, Alemtuzumab, Glatopa, Siponimod, Ocrelizumab, Laquinimod, Zinbryta), By Mode of Administration (Oral, Injectable, Intravenous) And Segment Forecasts To 2024

  • Published Date: May 2016
  • Report ID: 978-1-68038-833-6
  • Number of Pages: 80
  • Format: Electronic (PDF)
  • Historical Data: 2013-2015

Table of Content

Chapter 1 Methodology and Scope
                  1.1 Research Methodology
                  1.2 Research Scope & Assumptions
                  1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Multiple sclerosis therapeutics Industry Outlook
                  3.1 Market Segmentation
                  3.2 Market Size and Growth Prospects
                       3.2.1 Market driver analysis
                               3.2.1.1 Increasing global prevalence of target disease
                               3.2.1.2 Awareness programs
                               3.2.1.3 Presence of reimbursement policies.
                               3.2.1.4 Strong product pipeline.
                       3.2.2 Market restraint analysis
                       3.2.3 Multiple sclerosis therapeutics market - Key market restraint analysis
                               3.2.3.1 Side-effects and risks
                               3.2.3.2 High price
                  3.3 Key Opportunities Prioritized
                  3.4 Multiple sclerosis therapeutics - PESTEL Analysis
Chapter 4 Multiple sclerosis therapeutics Drug Class Outlook
                  4.1 Multiple sclerosis therapeutics Market Share by Drug Class, 2015 & 2024
                  4.2 Immunomodulators
                       4.2.1 Immunomodulators market, 2012 - 2024 (USD Million)
                  4.3 Immunosuppressant
                       4.3.1 Immunosuppressantmarket, 2012 - 2024 (USD Million)
Chapter 5 Multiple sclerosis therapeutics Mode of Administration Outlook
                  5.1 Multiple sclerosis therapeutics Market Share by Mode of Administration, 2015 & 2024
                  5.2 Oral
                       5.2.1 Oral market, 2012 - 2024 (USD Million)
                  5.3 Injectable
                       5.3.1 Injectablemarket, 2012 - 2024 (USD Million)
                  5.4 Intravenous
                       5.4.1 Intravenousmarket, 2012 - 2024 (USD Million)
Chapter 6 Multiple sclerosis therapeutics Regional Outlook
                  6.1 Multiple sclerosis therapeutics Market Share by Region, 2015 & 2024
                  6.2 North America
                       6.2.1 North America Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
                       6.2.2 U.S.
                               6.2.2.1 U.S. multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
                       6.2.3 Canada
                               6.2.3.1 Canada multiple sclerosis therapeutics market, 2012 - 2024 (USD Million)
                  6.3 Europe
                       6.3.1 Europe Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
                       6.3.2 UK
                               6.3.2.1 UK Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
                       6.3.3 Germany
                               6.3.3.1 Germany Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
                  6.4 Asia Pacific Multiple sclerosis therapeutics Market
                       6.4.1 Asia Pacific Multiple sclerosis therapeutics Market, 2012 - 2020 (USD Million)
                       6.4.2 China
                               6.4.2.1 China Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
                       6.4.3 India
                               6.4.3.1 India Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
                  6.5 Latin America
                       6.5.1 Latin America Multiple sclerosis therapeutics Market, 2012 - 2022 (USD Million)
                       6.5.2 Brazil
                               6.5.2.1 Brazil Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
                  6.6 MEA
                       6.6.1 MEA Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
                       6.6.2 South Africa
                               6.6.2.1 South Africa Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
Chapter 7 Competitive Landscape
                  7.1 Teva
                       7.1.1 Company Overview
                       7.1.2 Financial Performance
                       7.1.3 Product Benchmarking
                       7.1.4 Strategic Initiatives
                  7.2 Pfizer
                       7.2.1 Company Overview
                       7.2.2 Financial Performance
                       7.2.3 Product Benchmarking
                       7.2.4 Strategic Initiatives
                  7.3 Biogen Idec
                       7.3.1 Company Overview
                       7.3.2 Financial Performance
                       7.3.3 Product Benchmarking
                       7.3.4 Strategic Initiatives
                  7.4 Bayer Healthcare
                       7.4.1 Company Overview
                       7.4.2 Financial Performance
                       7.4.3 Product Benchmarking
                       7.4.4 Strategic Initiatives
                  7.5 Genzyme (SANOFI)
                       7.5.1 Company Overview
                       7.5.2 Financial Performance
                       7.5.3 Product Benchmarking
                       7.5.4 Strategic Initiatives


List of Tables

TABLE 1 Multiple sclerosis therapeutics market - Industry Summary & Critical Success Factors (CSFs)
TABLE 2 Multiple sclerosis therapeutics market, by treatment, 2012 - 2024 (USD Million)
TABLE 3 Multiple sclerosis therapeutics market, by region, 2012 - 2024 (USD Million)
TABLE 4 Multiple sclerosis therapeutics market - Key market driver analysis
TABLE 5 Immunomodulators market: Drug overview
TABLE 6 Immunosuppressant market: Drug overview
TABLE 7 Oral drugs market: Drug overview
TABLE 8 Injectable market: Drug overview
TABLE 9 Intravenous market: Drug overview
TABLE 10 North America multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 11 U.S. multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 12 Canada multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 13 Europe multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 14 UK multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 15 Germany multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 16 Asia Pacific multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 17 China Multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 18 India Multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 19 Latin America multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 20 Brazil multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 21 MEA multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 22 South Africa multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 23 MEA multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 24 MEA multiple sclerosis therapeutics market, by treatment, 2012 - 2024 (USD Million)


List of Figures

FIG. 1 Multiple Sclerosis Therapeutics: Market Segmentation
FIG. 2 Global Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 3 Multiple sclerosis therapeutics Market Dynamics
FIG. 4 Key Opportunities Prioritized
FIG. 5 Multiple sclerosis therapeutics market - Porter’s analysis
FIG. 6 Multiple sclerosis therapeutics market - PESTEL analysis
FIG. 7 Multiple sclerosis therapeutics Market Share By Drug Class, 2015 & 2024
FIG. 8 Global immunomodulators market, 2012 - 2024 (USD Million)
FIG. 9 Global Immunosuppressant market, 2012 - 2024 (USD Million)
FIG. 10 Multiple sclerosis therapeutics Market Share By Drug Class, 2015 & 2024
FIG. 11 Global oral market, 2012 - 2024 (USD Million)
FIG. 12 Global Injectable market, 2012 - 2024 (USD Million)
FIG. 13 Global Intravenous market, 2012 - 2024 (USD Million)
FIG. 14 Multiple sclerosis therapeutics Market Share by Region, 2015 & 2024
FIG. 15 North America Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 16 U.S. Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 17 Canada multiple sclerosis therapeutics market, 2012 - 2024 (USD Million)
FIG. 18 Europe Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 19 UK Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 20 Germany Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 21 Asia Pacific Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 22 China Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 23 India Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 24 Latin America Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 25 Brazil Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 26 MEA Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 27 South Africa Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 28 MEA Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.